- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06370832
Treinamento muscular inspiratório em candidatos a transplante pulmonar
Treinamento muscular inspiratório em candidatos a transplante pulmonar e implicações nos resultados pós-transplante precoce: um ensaio clínico piloto e de viabilidade randomizado
Recovery after lung transplantation (LTx) may be complicated by prolonged mechanical ventilation (MV) and protracted intensive care unit (ICU) stay leading to immobilization and impaired health-related quality of life (HRQoL). In the critical care setting, diaphragm atrophy and weakness have been associated with difficulty weaning from MV, increased risk for readmission to hospital or ICU, and increased mortality. Increasing respiratory muscle strength by inspiratory muscle training (IMT) as part of pre-rehabilitation mitigates respiratory muscle dysfunction peri-operatively and may reduce the risk of post-operative complications. However, IMT is not widely used prior to LTx and the benefits of pre-operative IMT on post-transplant outcomes in LTx candidates have not been studied. Objectives: (1) To evaluate the feasibility of a multicenter randomized clinical trial of IMT in LTx candidates in terms of recruitment rate, retention, program adherence, and outcome ascertainment; (2) To establish the change in pre-transplant dyspnea perception, diaphragm structure and function, health related quality of life (HRQoL) and post-transplant intensive care unit (ICU), hospital and post-transplant 3-month outcomes with IMT relative to usual care group; and (3) To characterize the effect of pre-transplant IMT on peri-transplant diaphragm myofibrillar cross-sectional area (CSA), oxidative capacity, inflammatory markers and post-transplant diaphragm muscle thickness and function (UHN TGH site).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Diaphragm atrophy at the time of initiating mechanical ventilation (MV) after solid organ transplantation and major surgery is associated with prolonged MV and higher hospital mortality. The incidence of diaphragm dysfunction after LTx is estimated to be up to 30%; post-transplant diaphragm dysfunction is associated with prolonged MV and hospitalization after LTx.
The American Thoracic Society/European Respiratory Society (2013) guidelines recommend further evaluation of inspiratory muscle training (IMT) combined with routine rehabilitation prior to major surgery. Pre-operative IMT in patients with even normal maximal inspiratory pressures (MIP) have been shown to decrease post-operative pulmonary complications and shorten hospitalization after cardio-thoracic surgery. However, pre-operative IMT is not commonly used for LTx candidates and its benefits are poorly researched. IMT may prove to be a simple pre-transplant intervention to prevent post-transplant morbidity and improve post-transplant functional status. The current focus is to investigate the impact of IMT on early post-lung transplant results while evaluating its effectiveness through a pilot multicenter randomized controlled trial.
Objectives: 1) To evaluate the feasibility of a multicenter randomized clinical trial of IMT in LTx candidates in terms of recruitment rate, retention, program adherence, and outcome ascertainment.
2) To establish the change in pre-transplant dyspnea perception, diaphragm structure and function, health related quality of life (HRQoL) and post-transplant intensive care unit (ICU), hospital and post-transplant 3-month outcomes with IMT relative to usual care group.
3) To characterize the effect of pre-transplant IMT on peri-transplant diaphragm myofibrillar cross-sectional area (CSA), oxidative capacity, inflammatory markers and post-transplant diaphragm muscle thickness and function (UHN TGH site).
Hypotheses: 1) It will be feasible to recruit LTx candidates into an IMT program RCT with a consent rate ≥ 30 %, enrolment rate of 2-3 patients per month at UHN and 1 patient per month at each other participating site, adequate outcome ascertainment (≥ 80%), and acceptable adherence (≥ 80% compliance with IMT sessions). 2) IMT will increase respiratory muscle endurance by 20% and improve exertional dyspnea and HRQoL in comparison to usual care over the pre-transplant period. IMT will be associated with greater hospital free days at 90 days. 3) pre-transplant IMT increases diaphragm myofibrillar CSA and post-LTx diaphragm thickness and maximal diaphragm thickening during inspiration in comparison to usual care. The improved mitochondrial respiration will occur concurrently with improvements in muscle fiber size, immune infiltration and oxidative stress.
The IMT and exercise training group (IMT group) will perform two daily IMT sessions of 30 breaths (< 5 minutes/session) during the pre-LTx period. IMT will start at 30% of MIP with a 5-10% weekly increase in training intensity guided by weekly MIP as tolerated (median weekly Borg dyspnea score < 7 during IMT until reaching 70% of MIP) and continued until LTx. In conjunction with their IMT program, IMT group participants will undergo exercise training at least three times per week as part of their usual care. The control group (exercise training group) will perform exercise training as part of their usual care three times per week for the duration of the waitlist period. The exercise regimen for both groups consists of aerobic, resistance, and flexibility training supervised by a physiotherapist approximately three times a week. The training includes a combination of in-person visits and home-based sessions. Both groups will also receive a respiratory endurance device to evaluate respiratory endurance throughout the trial.
IMT can improve respiratory muscle strength and endurance, potentially helping those who are candidates for LTx. In addition, studying patients undergoing LTx affords unique opportunities to investigate the mechanistic effects of IMT on diaphragm structure and function.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Dmitry Rozenberg, MD, PhD
- Número de telefone: 7358 416-340-4800
- E-mail: Dmitry.Rozenberg@uhn.ca
Locais de estudo
-
-
Alberta
-
Edmonton, Alberta, Canadá, T6G 2G3
- Recrutamento
- Edmonton Lung Transplant Program
-
Contato:
- Kieran Halloran, MD
- Número de telefone: (780) 492-2691
- E-mail: kieran@ualberta.ca
-
-
British Columbia
-
Vancouver, British Columbia, Canadá
- Recrutamento
- Vancouver General Hospital
-
Contato:
- Jordan Guenette, PhD
- Número de telefone: 604-806-8835
- E-mail: Jordan.Guenette@hli.ubc.ca
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 2C4
- Recrutamento
- University Health Network
-
Contato:
- Dmitry Rozenberg, MD, PhD
- Número de telefone: 7358 416-340-4800
- E-mail: dmitry.rozenberg@uhn.ca
-
-
Quebec
-
Montreal, Quebec, Canadá
- Recrutamento
- Centre hospitalier de l'Université de Montréal (CHUM)
-
Contato:
- Tania Janaudis-Ferreira, PhD
- Número de telefone: 514-619-0871
- E-mail: tania.janaudis-ferreira@mcgill.ca
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Adult participants (≥ 18 years of age)
- Lung Transplant Candidates
- Participating in outpatient pulmonary rehabilitation (standard of care)
- Diagnosis of Interstitial Lung Disease or Chronic Obstructive Pulmonary Disease
Exclusion Criteria:
- Respiratory exacerbation within the last 1 month
- Neurologic or musculoskeletal conditions that may interfere with IMT or functional assessments (i.e. history of stroke, severe arthritis of hands)
- Insufficient English fluency to provide informed consent or to follow study protocols
- Any evidence of pneumothorax on recent imaging (< 6 months)
- Present ruptures of eardrums or infections leading to fluid behind ear drum
- Marked left or right ventricular end-diastolic volume and pressure overload on right heart catheterization or echocardiogram
- Severe osteoporosis with history of rib fractures
- Cardiac pacemaker or other electronic or magnetic body implant
- Individuals listed as rapidly deteriorating or inpatient at the time of eligibility assessment
- Individuals awaiting a re-transplant
- Inability of the patient to connect to the internet
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: IMT and exercise training group
Participants in the IMT and exercise training group will perform twice daily 30-breath IMT sessions and exercise training sessions three times per week as part of their usual care during the pre-lung transplant phase. The exercise training is comprised of aerobic, resistance and flexibility training. |
Participants will perform supervised exercise training per usual care and will be provided with a personalized prescription for an IMT program during the pre-transplant phase. Participants will perform two daily IMT sessions of 30 breaths (< 5 minutes/session) 5 days per week in their home environment or in-person visits. IMT intensity will be progressed weekly by 5-10% of the baseline maximal inspiratory pressure if the Borg Dyspnea score is < 7. |
|
Sem intervenção: Usual care group
Participants in the usual care group will take part in the standard of care rehabilitation program provided during the waitlist phase prior to the transplant. Exercise training is performed at least three times per week for the duration of the waitlist period. The exercise training includes a combination of supervised in-person visits and home-based training that incorporates aerobic, resistance and flexibility training. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Study Recruitment According to Research Team Records
Prazo: Over study recruitment period (approximately 2 years)
|
Recruitment-success percentage in the study will be assessed based on research team study records. |
Over study recruitment period (approximately 2 years)
|
|
Participant Retention in the Study According to Research Team Records
Prazo: Over the study data collection period (from enrolment until 3 months post-transplant)
|
Participant retention will be assessed by measuring participant follow-up throughout the study period, according to research team records. A retention rate of 80% or greater (in each group) has been established as the criteria to determine study feasibility. |
Over the study data collection period (from enrolment until 3 months post-transplant)
|
|
Self-Reported Adherence to Inspiratory Muscle Training According to Participant IMT Diary
Prazo: Over intervention period (from randomization until time of transplantation, up to maximum of 24 months)
|
Adherence to inspiratory muscle training will be assessed via the IMT training diary completed by participants. Successful adherence will be defined as completion of ≥ 80% training sessions. |
Over intervention period (from randomization until time of transplantation, up to maximum of 24 months)
|
|
Adverse Events and IMT Training Side Effects Reported by Participants
Prazo: Over intervention period (from randomization until time of transplantation, up to maximum of 24 months)
|
Adverse events and training side-effects (e.g., muscle soreness) with inspiratory muscle training will be monitored through participant training diaries during the study intervention period. The research coordinator will review these diaries with participants on a weekly basis. Additionally, participants will be strongly encouraged to promptly inform the study team if they experience any challenges with IMT. |
Over intervention period (from randomization until time of transplantation, up to maximum of 24 months)
|
|
Inspiratory Muscle Training Satisfaction Questionnaire (IMT Group Only)
Prazo: At 3 months post-transplant follow-up
|
Participant satisfaction and motivation with the IMT intervention will be determined using a satisfaction questionnaire. |
At 3 months post-transplant follow-up
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Respiratory Muscle Endurance Test
Prazo: Change from baseline at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant
|
Respiratory muscle endurance (measured in seconds) will be assessed at 30-50% of Maximum Inspiratory Pressure (MIP) using a manual threshold loading device (Powerbreathe Classic light resistance trainer) |
Change from baseline at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant
|
|
Dyspnea Severity Assessed by Medical Research Council Dyspnea Scale
Prazo: Change from baseline at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant
|
The Medical Research Council Dyspnea Scale will be used to assess the effect of breathlessness on daily activities. The scale comprises five statements that describe the range of respiratory dyspnea from none (Grade 1) to severe with difficulties performing self-care (Grade 5). |
Change from baseline at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant
|
|
Qualitative Measures of Dyspnea Assessed by Qualitative Dyspnea Scale
Prazo: Change from baseline at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant
|
The 18-point Qualitative Dyspnea Scale will be ascertained at each follow-up time point. Participants will be presented with a list of 18 qualitative descriptors of dyspnea experience and will be asked to rank their top three. |
Change from baseline at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant
|
|
Mood Assessed by Depression, Anxiety, and Stress Scale
Prazo: Change from baseline at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant
|
The Depression, Anxiety and Stress Scale (DASS-21) questionnaire has 21 items to assess mood (anxiety, depression, and stress). Each statement for the three domains is given a score of 0 (not applicable) to 3 (applicable most of the time) with scores categorized as follows: Normal, Mild, Moderate, Severe, and Extremely Severe. |
Change from baseline at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant
|
|
Health-Related Quality of Life Assessed by St. George's Respiratory Questionnaire
Prazo: Change from baseline at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant
|
Health-related Quality of Life (HRQL) will be assessed through the St. George's Respiratory Questionnaire (SGRQ) and consists of three domains (symptoms, activity and impacts) and total score. The SGRQ has a range of scores from 0 to 100 with higher scores signifying worse HRQL. |
Change from baseline at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant
|
|
Respiratory Muscle Strength Assessed by Maximal Inspiratory Pressure
Prazo: Change from baseline at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), time of liberation from mechanical ventilation, and 3 months post-transplant
|
Respiratory muscle strength will be quantified as Maximal Inspiratory Pressure (MIP), evaluated using a respiratory muscle trainer (PowerBreathe KH2). |
Change from baseline at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), time of liberation from mechanical ventilation, and 3 months post-transplant
|
|
Physical Activity and Exercise Behaviors Assessed by International Physical Activity Questionnaire
Prazo: Change from baseline at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant
|
The International Physical Activity Questionnaire - Short Form (IPAQ-SF) will be used to measure physical activity levels in study participants. The questionnaire consists of seven questions to capture average daily time spent sitting, walking, and engaging in moderate and vigorous physical activity over the last seven days. The IPAQ-SF provides an overall physical activity level of participants based on their Metabolic Equivalent Task minutes per week. |
Change from baseline at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant
|
|
Pulmonary Function Testing (Spirometry)
Prazo: Baseline, 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant
|
Clinical charts will be reviewed to obtain results from spirometry assessments including Forced Vital Capacity (FVC), and Forced Expiratory Volume in the first second (FEV1). |
Baseline, 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant
|
|
Aerobic Endurance Assessed by the Six-Minute Walk Test
Prazo: Baseline, 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant
|
Clinical rehabilitation charts will be reviewed to document aerobic endurance as assessed by distance walked during the Six-Minute Walk Test. |
Baseline, 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant
|
|
Physical Function Assessed by the Short Physical Performance Battery
Prazo: Baseline, 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant
|
Clinical rehabilitation charts will be reviewed to document physical function as assessed by the Short-Physical Performance Battery, which evaluates balance, gait speed, and ability to rise from a chair 5 times. |
Baseline, 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant
|
|
Pre-Transplant Hospitalizations
Prazo: From baseline up until the time of admission for the index transplant hospitalization (up to 24 months total)
|
Clinical charts will be reviewed to document any hospitalizations and ICU admissions before the time of transplantation. |
From baseline up until the time of admission for the index transplant hospitalization (up to 24 months total)
|
|
Peri-Transplant Mechanical Ventilation Bridging
Prazo: Peri-operative period, from time of index transplant hospital admission to time of transplant surgery (up to 24 months total)
|
Clinical charts will be reviewed to determine whether mechanical ventilation or extracorporeal membrane oxygenation (ECMO) were required as a bridge to transplantation. |
Peri-operative period, from time of index transplant hospital admission to time of transplant surgery (up to 24 months total)
|
|
Post-Transplant Duration of Mechanical Ventilation (Days)
Prazo: From time of transplant surgery to the time of liberation from mechanical ventilation (up to 3 months total)
|
Clinical charts will be reviewed to determine the duration of mechanical ventilation required following transplantation surgery, measured in days. |
From time of transplant surgery to the time of liberation from mechanical ventilation (up to 3 months total)
|
|
WIND Weaning Classification
Prazo: At the time of liberation from mechanical ventilation following transplant surgery (up to 3 months total).
|
The WIND weaning classification (short, difficult, or prolonged) will be ascertained by ICU staff at the time of liberation from mechanical ventilation based on the number of spontaneous breathing trials and weaning difficulty. |
At the time of liberation from mechanical ventilation following transplant surgery (up to 3 months total).
|
|
Post-Transplant Hospital Length of Stay (Days)
Prazo: From time of transplant surgery to the time of discharge from hospital (up to 3 months total).
|
Clinical charts will be reviewed to determine the length of stay in hospital following transplant surgery, measured in days. |
From time of transplant surgery to the time of discharge from hospital (up to 3 months total).
|
|
Post-Transplant Discharge Disposition
Prazo: Time of discharge from index transplant hospitalization (up to 3 months total).
|
Clinical charts will be reviewed to determine participants' discharge disposition from the index transplant hospitalization (e.g., home, inpatient rehabilitation, long-term care). |
Time of discharge from index transplant hospitalization (up to 3 months total).
|
|
Primary Graft Dysfunction
Prazo: Up to 72 hours post-transplant
|
Clinical charts will be reviewed to determine the presence and severity of primary graft dysfunction following transplant surgery. |
Up to 72 hours post-transplant
|
|
Post-Transplant Mortality
Prazo: Up to 90 days (3 months) post-transplant
|
Clinical charts will be reviewed to document post-transplant mortality and etiology. |
Up to 90 days (3 months) post-transplant
|
|
Days Alive and at Home at 90 Days (DAAH90)
Prazo: Up to 90 days (3 months) post-transplant
|
Clinical charts will be reviewed to determine the number of days participants are alive and at home at 90 days post-transplant. |
Up to 90 days (3 months) post-transplant
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Diaphragm Thickness and Thickening Fraction Assessed by Ultrasound
Prazo: Change from baseline to all on-site visits at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), time of liberation from MV, and 3 months post-transplant
|
The right hemi-diaphragm thickness and thickening fraction will be measured using a 13 Megahertz ultrasound transducer. Bright-mode (B-mode) ultrasound will be used to visualize the diaphragm and motion-mode (M-mode) will be utilized to assess the amplitude of the cranio-caudal diaphragmatic excursion during quiet and deep breathing. Diaphragm thickness will be measured in M-mode with a 5-13 MHz linear transducer over the apposition zone, near the costophrenic angle, from the most superficial hyperechoic line (pleural line) to the deepest hyperechoic line (peritoneal line). |
Change from baseline to all on-site visits at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), time of liberation from MV, and 3 months post-transplant
|
|
Histopathology Analyses of Diaphragm Biopsies (Optional)
Prazo: At the time of lung transplantation, up to maximum of 24 months after randomization
|
Participants will have the option of consenting to diaphragm biopsies collected during the transplant surgery. Biopsies (50 mg) will be procured from the anterolateral region of the right costal hemi-diaphragm midway between the origin and insertion. A portion of the tissue sample (20mg) will be fixed in formalin for histopathology analyses including assessing fibre type distribution, fibre type-specific cross-sectional area, immune infiltration, oxidative capacity, and fibrosis using light microscopy. |
At the time of lung transplantation, up to maximum of 24 months after randomization
|
|
Biochemical Analyses of Diaphragm Biopsies (Optional)
Prazo: At the time of lung transplantation, up to maximum of 24 months after randomization
|
A second tissue portion (20mg) will be flash frozen in liquid nitrogen to assess mitochondrial content (via western blotting) and signaling cascades to examine atrophic signaling cascades using polymerase chain reactions. |
At the time of lung transplantation, up to maximum of 24 months after randomization
|
|
Mitochondrial Respirometry Analyses of Diaphragm Biopsies (Optional)
Prazo: At the time of lung transplantation, up to maximum of 24 months after randomization
|
The final tissue portion (10 mg) will be used for live assessments of mitochondrial function using the Oroboros O2K High Resolution Respiratory system on the day of transplantation, as quickly after biopsy collection as possible. |
At the time of lung transplantation, up to maximum of 24 months after randomization
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Dmitry Rozenberg, MD, PhD, University Health Network/University of Toronto
Publicações e links úteis
Publicações Gerais
- Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, Lederer DJ, Mulligan MJ, Patterson GA, Singer LG, Snell GI, Verleden GM, Zamora MR, Glanville AR. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015 Jan;34(1):1-15. doi: 10.1016/j.healun.2014.06.014. Epub 2014 Jun 26.
- Adler D, Dupuis-Lozeron E, Richard JC, Janssens JP, Brochard L. Does inspiratory muscle dysfunction predict readmission after intensive care unit discharge? Am J Respir Crit Care Med. 2014 Aug 1;190(3):347-50. doi: 10.1164/rccm.201404-0655LE. No abstract available.
- Hook JL, Lederer DJ. Selecting lung transplant candidates: where do current guidelines fall short? Expert Rev Respir Med. 2012 Feb;6(1):51-61. doi: 10.1586/ers.11.83.
- Fuehner T, Kuehn C, Welte T, Gottlieb J. ICU Care Before and After Lung Transplantation. Chest. 2016 Aug;150(2):442-50. doi: 10.1016/j.chest.2016.02.656. Epub 2016 Mar 4.
- Christie JD, Kotloff RM, Ahya VN, Tino G, Pochettino A, Gaughan C, DeMissie E, Kimmel SE. The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med. 2005 Jun 1;171(11):1312-6. doi: 10.1164/rccm.200409-1243OC. Epub 2005 Mar 11.
- Sklar MC, Dres M, Fan E, Rubenfeld GD, Scales DC, Herridge MS, Rittayamai N, Harhay MO, Reid WD, Tomlinson G, Rozenberg D, McClelland W, Riegler S, Slutsky AS, Brochard L, Ferguson ND, Goligher EC. Association of Low Baseline Diaphragm Muscle Mass With Prolonged Mechanical Ventilation and Mortality Among Critically Ill Adults. JAMA Netw Open. 2020 Feb 5;3(2):e1921520. doi: 10.1001/jamanetworkopen.2019.21520.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 22-5171
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .